HER3 radioimmunotherapy for the treatment of solid cancers

A method for treating a solid cancer comprising HER3-positive cancer cells in a mammalian subject, the method comprising:

• administering to a mammalian subject afflicted with a solid cancer comprising HER3-positive cancer cells a therapeutically effective amount of a radionuclide labeled HER3 targeting antibody comprising:
• radionuclide labeled barecetamab;
• radionuclide labeled patritumab;
• radionuclide labeled seribantumab;
• radionuclide labeled lumretuzumab;
• radionuclide labeled elgemtumab;
• a radionuclide labeled antibody comprising an immunoglobulin heavy chain variable region comprising a CDR-H1 comprising SEQ ID NO:15, a CDR-H2 comprising SEQ ID NO:16, and a CDR-H3 comprising SEQ ID NO:17, and an immunoglobulin light chain variable region comprising a CDR-L1 comprising SEQ ID NO:18, a CDR-L2 comprising SEQ ID NO:19, and a CDR-L3 comprising SEQ ID NO:20;
• a radionuclide labeled antibody comprising an immunoglobulin heavy chain variable region comprising SEQ ID NO:21 and an immunoglobulin light chain variable region comprising SEQ ID NO:22;
• or
• a radionuclide labeled antibody comprising an immunoglobulin heavy chain amino acid sequence of SEQ ID NO:23 and an immunoglobulin light chain amino acid sequence of SEQ ID NO:
• 24.